Edition:
United States

Morphosys AG (MORG.DE)

MORG.DE on Xetra

76.08EUR
11:35am EST
Change (% chg)

€-1.26 (-1.63%)
Prev Close
€77.34
Open
€77.40
Day's High
€77.44
Day's Low
€73.65
Volume
352,702
Avg. Vol
178,016
52-wk High
€83.83
52-wk Low
€44.75

Chart for

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.76
Market Cap(Mil.): €2,275.29
Shares Outstanding(Mil.): 29.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Morphosys Presents Clinical Data On MOR208 Plus Lenalidomide In Aggressive Lymphoma

* DGAP-NEWS: MORPHOSYS PRESENTS CLINICAL DATA ON MOR208 PLUS LENALIDOMIDE IN AGGRESSIVE LYMPHOMA (R/R DLBCL) AT ASH 2017 CONFERENCE

Dec 11 2017

BRIEF-Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

Dec 05 2017

BRIEF-Janssen receives approval for Tremfya in Europe - Morphosys

* Announces that its licensee Janssen has received approval for Tremfya(r) (guselkumab) in Europe for the treatment of moderate-to-severe plaque psoriasis

Nov 23 2017

BRIEF-Morphosys Q3 revenue up 20 pct at 15 mln eur​

* Q3 net loss -24 million eur versus -12.8 million eur loss year ago

Nov 07 2017

BRIEF-Morphosys names Enzelberger as new chief scientific officer

* Says Dr. Markus Enzelberger appointed chief scientific officer

Oct 30 2017

BRIEF-Morphosys says received FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

* DGAP-Adhoc: Adhoc: Morphosys receives FDA breakthrough therapy designation for its antibody MOR208 in Relapsed/Refractory DLBCL

Oct 23 2017

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

Sep 27 2017

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

Aug 31 2017

BRIEF-Morphosys affirms guidance after Q2 results

* dgap-news: morphosys reports significant progress in its therapeutic programs in second quarter of 2017

Aug 03 2017

Morphosys sees revenue boost from Janssen psoriasis drug

DUESSELDORF/FRANKFURT German biotech group Morphosys expects to receive royalties from psoriasis drug guselkumab for five months this year, its Chief Executive Simon Moroney said, after its licensee received U.S. regulatory approval.

Jul 14 2017

Earnings vs. Estimates